Company intelligence / Profile preview
Beijing Genova Biotech
Beijing, Beijing, Chinagenova.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Novaferon (interferon alpha/beta receptor fusion protein) is approved in China for hepatitis B and has demonstrated antiviral and immunomodulatory potency. Nova-EPO and Nova-GM-CSF are in preclinical stages. The company has additional programs for metabolic/endocrine diseases, including biosimilars for insulin and growth hormone heading into or recently completed EU trials.
- Therapeutic areas
- Infectious DiseasesOncologyHematologyEndocrinology
- Modalities
- Recombinant proteinFusion proteinCytokineColony-stimulating factor
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
CDMO service partnerships for nucleic acid vaccine manufacturingCollaborations with EU/EMA for biosimilar trials
Beyond the preview
Go deeper on Beijing Genova Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Genova Biotech.